Recent Updates
Recently added Catalysts
ADMA Negative Sentiment Score: 20/100

ADMA LAWSUIT: ADMA Biologics, Inc. Sued For Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses

Key Takeaway: ADMA Biologics, Inc. has been sued for securities fraud by Block & Leviton, alleging that the company misled investors regarding its revenue growth from ASCENIV. The complaint claims that ADMA engaged in a channel-stuffing scheme and failed to disclose a related-party distribution relationship with Genesis BioPharma Services. Following a report by Culper Research revealing these issues, ADMA's stock price fell dramatically. Investors affected by these developments are encouraged to contact the law firm for potential recovery options.

Market Sentiment Analysis

CONCERNS & RISKS

  • ADMA Biologics is facing a lawsuit for securities fraud, potentially damaging its reputation.
  • The lawsuit alleges misleading revenue growth practices, which may result in legal penalties.
  • ADMA's stock price experienced a significant drop from $13.59 to $8.29 following negative revelations.

Full Press Release Details

BOSTON, June 10, 2026 (GLOBE NEWSWIRE) -- Block & Leviton announces that a securities fraud lawsuit has been filed against ADMA Biologics, Inc. (Nasdaq: ADMA) and certain of its executives. Investors who have lost money in their ADMA Biologics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/adma.
What is this all about?
The complaint alleges that ADMA Biologics misled investors about the source of its revenue growth by engaging in a channel-stuffing scheme involving its flagship product, ASCENIV, and by failing to disclose an alleged related-party distribution relationship involving Genesis BioPharma Services. According to the complaint, the truth began to emerge on March 24, 2026, when Culper Research published a report claiming that ADMA's reported growth was driven by excess inventory shipments rather than genuine demand and that significant ASCENIV inventory remained unsold in distribution channels. Following the report, ADMA's stock price fell from approximately $13.59 per share to $8.29 per share by March 26, 2026.
Anyone who purchased ADMA Biologics, Inc. stock between August 9, 2024, and March 25, 2026, and has seen their shares fall may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more.
What should you do next?
The deadline to seek appointment as lead plaintiff is August 10, 2026. A class has not yet been certified, and until a certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. If you've lost money on your investment, you should contact Block & Leviton to learn more via our case website, by email at shareholders@blockleviton.com, or by phone at (888) 256-2510.
If you have non-public information about ADMA Biologics, Inc., you should consider assisting in our investigation or working with our attorneys to file a report with the Securities Exchange Commission under their whistleblower program. Whistleblowers who provide original information to the SEC may receive rewards of up to 30% of any successful recovery. For more information, contact Block & Leviton at whistleblowers@blockleviton.com or by phone at (888) 256-2510.
Why should you contact Block & Leviton?
Block & Leviton is widely regarded as one of the leading securities class action firms in the country. Our attorneys have recovered billions of dollars for defrauded investors and are dedicated to obtaining significant recoveries on behalf of our clients through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website, www.blockleviton.com, call (888) 256-2510 or email shareholders@blockleviton.com with any questions.
This notice may constitute attorney advertising.
260 Franklin St., Suite 1860
Phone: (888) 256-2510

Tags

Frequently Asked Questions

What is the lawsuit against ADMA Biologics about?

The lawsuit claims ADMA misled investors about its revenue growth through a channel-stuffing scheme.

How did ADMA Biologics' stock price change?

ADMA's stock price dropped from $13.59 to $8.29 after a negative report on March 24, 2026.

Who can join the lawsuit against ADMA Biologics?

Investors who bought ADMA stock from August 9, 2024, to March 25, 2026, may be eligible.

How can investors contact Block & Leviton?

Investors can reach Block & Leviton at (888) 256-2510 or via email at shareholders@blockleviton.com.

What is the deadline to be a lead plaintiff?

The deadline to seek lead plaintiff status is August 10, 2026.

Last updated: Jun 11, 2026